We are seeing how big the Imugene story can be with
the increasing flow of information which is becoming available.
In 2019 Merck bought out Arqule an oncolgy company, whose
promising drug ARQ531 was in a Phase 2 expansion study for
treatment of B cell malignancies. Merck paid shareholders $20 US
per share cash and the prior share price was $4-5.00 US
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 5795292 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3258567 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |